← Archive

Three Acquisitions in 75 Days: The NICU Technology Stack Is Consolidating, and Not Everyone Will Get a Seat at the Table

Natus Sensory acquired Keriton and TheraB Medical in 14 days. AngelEye Health acquired SupportSpot 44 days later. Three NICU deals in one quarter are rewriting the vendor consolidation logic for neonatal care — and compressing the window for everyone still building independently.

A Platform Nobody Planned to Build

Start with a simple question: what does a NICU look like from a technology vendor's perspective?

A bit of a maze. A level IV NICU at a major children's hospital might route through GE HealthCare or Philips for core bedside monitoring, Masimo for pulse oximetry, Natus for hearing screening, a separate vendor for neuromonitoring, another for feeding management software, a camera system for family engagement, yet another platform for discharge coordination, and a milk bank or nutrition supplier on top of that. Each of these vendors has its own contract, its own interface, its own training burden on nursing staff, and its own support relationship with the hospital. The NICU care team, which is already stretched by a documented nursing shortage, navigates all of it.

This is not a new problem. What is new is that two separate companies decided to do something about it in the same 90-day window.

Natus Sensory — headquartered in Middleton, Wisconsin, founded in 1987, and long one of the more important neonatal incumbents in hearing screening, phototherapy, and neurological monitoring — did not announce a platform strategy. It simply executed one. On January 28, it acquired Keriton, a Philadelphia-based NICU feeding management software company that had validated more than 4 million feeds and prevented more than 120,000 errors across 60 hospitals including Jefferson Health, New York Presbyterian, and Intermountain Healthcare. On February 11 — fourteen days later — it acquired TheraB Medical, an East Lansing startup that had received FDA 510(k) clearance for SnugLit just two weeks prior. SnugLit is the first FDA-cleared wearable swaddle-style phototherapy device for neonatal jaundice, allowing treatment while the infant remains with caregivers for holding and breastfeeding — a meaningful departure from the stationary bili lights that have been the NICU standard for decades.

Two acquisitions. Fourteen days. Neither company was particularly well-capitalized: Keriton raised roughly $3–4M in its lifetime, TheraB an undisclosed seed. Both were building toward a meaningful clinical need in a focused NICU workflow layer.

Then, on March 25, AngelEye Health acquired SupportSpot from Child Life On Call. AngelEye (a Nashville-based NICU platform with 350+ hospital relationships, $35M raised, and a recent Series C extension with Nationwide Children's Hospital as a strategic investor) moved beyond its NICU communication core to absorb a pediatric family support platform covering psychosocial preparation, coping resources, and procedure education for children and families across inpatient settings. The move extends AngelEye's footprint from the NICU bed to the broader pediatric floor, and it uses the company's existing distribution to give SupportSpot something its previous home never could: immediate scale.

The U.S. fetal and neonatal care equipment market is projected to grow from $4.35 billion today to $7.57 billion by 2035. Three of those acquisitions just happened in the same quarter.

Why These Deals, Why Now

It would be easy to read this as a random cluster of exits. Founders who needed liquidity, buyers with balance sheet capacity, deals that happened to close in the same window. That reading is wrong.

Each acquisition slots into a specific layer of the neonatal care stack in a way that increases the acquirer's breadth without cannibalizing its existing product lines. This is vendor consolidation by design, not opportunistic deal-making.

Natus's pre-acquisition portfolio covered hearing screening (OAE and ABR systems), jaundice phototherapy (prior light-based systems), neurological monitoring (the Olympic Brainz Monitor), visual monitoring via NicView, and clinical workflow software via Neometrics. What it did not have: a feeding management layer. Keriton fills that gap precisely. And TheraB's SnugLit does not replace Natus's existing phototherapy devices — it extends the line into a wearable, family-friendly format for the growing share of NICU families and health systems that prioritize family-integrated care as a clinical and experience standard.

The result, post-acquisitions, is a Natus product stack that spans hearing, vision, neurological monitoring, phototherapy (traditional and wearable), feeding safety, and NICU case management. That is a bundle. Health systems managing four to six separate neonatal technology vendor relationships now have a credible reason to consolidate down to one — or at least two — if Natus packages and sells accordingly.

AngelEye's logic is different but structurally similar. The company has built its business on camera access and family communication, then layered in MilkTracker (breast milk management for families), NICU2Home (discharge coordination), and clinical AI tools under the AIVision and EDNA programs. SupportSpot adds evidence-based tools for the psychosocial preparation and coping side of the pediatric experience — the domain of child life specialists, which most hospitals cannot fully staff. AngelEye's installed base of 350+ hospitals is a distribution machine for SupportSpot. More importantly, SupportSpot's expansion into general pediatric inpatient settings gives AngelEye a path to revenue beyond the NICU.

The timing matters. Health systems have been very clear in their capital planning signals for 2026: they want fewer vendors, longer contracts, and more interoperability. The NICU is not exempt from that consolidation pressure. A platform that can offer feeding safety, family engagement, discharge coordination, and family psychosocial support under a single master service agreement is a different conversation from four separate renewals. Natus and AngelEye are both betting that health systems will pay a premium — or at minimum grant preferential contract renewal — for that kind of integration.

Who's Left in the Open Field — and How Long the Window Stays Open

Three acquisitions in 90 days is a data point. It becomes a trend when you map what remains unacquired and unbuilt in the NICU technology stack.

Sibel Health, with its ANNE One platform and $33M+ raised, remains independent and is competing directly against incumbent hardware vendors on their home turf. Sibel has FDA clearance and clinical evidence — including a $5M Gates Foundation grant in April 2026 tied to ANNE Maternal clearance and AI features — and it has not had a liquidity event. That makes it either an acquisition target or a company that intends to build its own direct-to-health-system platform.

Neuromonitoring for neonates is simultaneously more crowded and more technically complex. Ceribell and CergenX are building AI-powered seizure detection and brain monitoring tools that overlap with Natus's Olympic Brainz Monitor territory. Neither is an obvious Natus tuck-in — both have independent commercialization ambitions, and Ceribell has already filed for an IPO. But the clinical territory they occupy is directly adjacent to the monitoring stack Natus is assembling, and if Natus wants to defend its neuromonitoring position against AI-native competitors, a defensive acquisition in this space is not implausible.

The discharge coordination and hospital-to-home transition layer is the most striking open wedge. Research shows that 68.5% of technology-dependent infants experience delayed discharge — with an average delay of 53 to 90 days and $450,000 in avoidable costs per child. The 90-day readmission rate for this population after discharge is 53.7%. No purpose-built startup has yet achieved meaningful scale in this space.

Family education and parent engagement — the narrower wedge that Nicolette occupies with its NicoBoard product — is a real category that remains thinly capitalized. Nicolette converts raw NICU EMR data into parent-friendly tools, visual trends, and care participation guidance. The clinical evidence for family-integrated care is strong: a 2025 systematic review confirmed reductions in NICU length of stay, infection rates, and breastfeeding barriers when family engagement is properly supported. AngelEye's SupportSpot acquisition may be the proof point that changes the buyer conversation for this entire category.

The NICU founder or investor watching this consolidation wave should sit with a specific question: is my company better positioned as a standalone platform, or as a strategic asset for Natus or AngelEye in the next 24 months? For companies in feeding operations, therapeutic devices, or family engagement — where the Keriton and TheraB exits set precedent — the answer is probably the latter, and the negotiating window is open now. For companies in AI-native clinical decision support, wireless monitoring, or discharge coordination, there is a real case for building toward a larger independent outcome — but the window for doing so without a well-resourced competitor occupying the same lane is not unlimited.

The NICU is a small market by health care standards, serving 380,000 admissions per year. It is also the most concentrated, most emotionally resonant, and most measurably high-cost point of care in all of pediatrics. The companies that assemble the right combination of workflow, family engagement, and clinical intelligence inside that environment will be very hard to displace. The acquisitions of January, February, and March 2026 suggest that race is already underway — and that at least two players have decided not to wait for someone else to run it.

What We're Watching

• Whether Natus Sensory integrates Keriton and Neometrics into a unified NICU clinical workflow product and begins offering a bundled procurement package to health systems. The commercial execution, not the acquisition itself, is the signal. Watch for joint product announcements, combined contract announcements at major health systems, or changes in Natus's sales leadership or go-to-market structure in Q3 2026.
• Whether AngelEye pursues additional acquisitions in pediatric inpatient family support, building on SupportSpot toward a broader pediatric engagement platform. The company's Nationwide Children's Hospital strategic investment and its stated AI expansion give it credibility for a pediatric platform pitch beyond the NICU.
• Whether Sibel Health reaches a commercialization or liquidity inflection before a major neonatal incumbent moves on its wireless monitoring position. Sibel's FDA clearances, $38M+ raised, and clinical evidence make it one of the most compelling independent assets in the NICU stack.